- Home
- EHC vs PCVX Comparison
EHC vs PCVX Comparison
Compare EHC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHC | PCVX |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 6.1B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EHC | PCVX |
|---|---|---|
| Price | $96.90 | $55.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $143.29 | $98.33 |
| AVG Volume (30 Days) | 793.6K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 24.22 | N/A |
| EPS | ★ 5.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.38 | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | $17.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $92.77 | $28.09 |
| 52 Week High | $127.99 | $75.33 |
Technical Indicators
Market Signals| Indicator | EHC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 31.62 | 46.65 |
| Support Level | $92.77 | $42.30 |
| Resistance Level | $109.14 | $56.04 |
| Average True Range (ATR) | 2.96 | 2.50 |
| MACD | -1.09 | -0.75 |
| Stochastic Oscillator | 2.07 | 24.34 |
Price Performance
Historical ComparisonAbout EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.